Another pharmacological class with high potential in the treatment of resistant hypertension to reduce BP values and outcomes, particularly HF, is represented by glyphozines (or Sodium-Glucose Cotransporter 2 Inhibitors). This evidence concerns the gene SLC5A2 and hypertensive disorder.